阿芬太尼在儿童体内的群体药代动力学。

IF 2.9 4区 医学
Lorena Medina-Aymerich, Ngoc Betty Ngo, Daniel Gonzalez, Chi D Hornik, Amira Al-Uzri, Rachel G Greenberg, Sarah G Anderson, Elizabeth H Payne, Sitora Turdalieva, Stephen J Balevic
{"title":"阿芬太尼在儿童体内的群体药代动力学。","authors":"Lorena Medina-Aymerich, Ngoc Betty Ngo, Daniel Gonzalez, Chi D Hornik, Amira Al-Uzri, Rachel G Greenberg, Sarah G Anderson, Elizabeth H Payne, Sitora Turdalieva, Stephen J Balevic","doi":"10.1002/jcph.70044","DOIUrl":null,"url":null,"abstract":"<p><p>Alfentanil is an opioid analgesic and anesthetic agent used in surgical procedures. Despite its widespread use in children, the U.S. Food and Drug Administration label lacks specific dosing recommendations for those under 12 years. A population pharmacokinetic analysis was performed using NONMEM (v7.5) to characterize alfentanil's disposition in children. The study included 58 plasma concentrations from 42 patients who received intravenous alfentanil as part of usual care. Median age was 7.57 years (range: 0.33-17.80) and median dosing was 12.5 mcg/kg (range: 4-43). A one-compartment model with first-order elimination best described alfentanil's pharmacokinetics. Among body size measures, total body weight (WT) significantly influenced clearance (CL [L/h]) = 7.42 × (WT/70)<sup>0.75</sup>) and volume of distribution (V [L]) = 12.6 × (WT/70)1). Inter-individual variability decreased after the inclusion of WT, coefficients of variation were reduced from 104% to 58% and from 169% to 83%, for CL and V, respectively. The final model facilitated simulations to achieve target efficacious analgesic and anesthetic concentrations. For analgesia, an initial 10 mcg/kg bolus (for the first hour) followed by an 8 mcg/kg/h infusion (starting at 1 h) achieved the efficacious targeted concentrations (10-100 ng/mL). For procedures that typically require minimal or moderate sedation, a 25 mcg/kg bolus followed by a 20 mcg/kg/h infusion (starting at 5 min) achieved the targeted concentrations (50-200 ng/mL, depending on the procedure). These regimens should be prospectively evaluated to ensure their safety and confirm their efficacy. Overall, this study provides valuable insights into pharmacokinetics and dosing of alfentanil in children.</p>","PeriodicalId":48908,"journal":{"name":"Journal of Clinical Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Population Pharmacokinetics of Alfentanil in Children.\",\"authors\":\"Lorena Medina-Aymerich, Ngoc Betty Ngo, Daniel Gonzalez, Chi D Hornik, Amira Al-Uzri, Rachel G Greenberg, Sarah G Anderson, Elizabeth H Payne, Sitora Turdalieva, Stephen J Balevic\",\"doi\":\"10.1002/jcph.70044\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Alfentanil is an opioid analgesic and anesthetic agent used in surgical procedures. Despite its widespread use in children, the U.S. Food and Drug Administration label lacks specific dosing recommendations for those under 12 years. A population pharmacokinetic analysis was performed using NONMEM (v7.5) to characterize alfentanil's disposition in children. The study included 58 plasma concentrations from 42 patients who received intravenous alfentanil as part of usual care. Median age was 7.57 years (range: 0.33-17.80) and median dosing was 12.5 mcg/kg (range: 4-43). A one-compartment model with first-order elimination best described alfentanil's pharmacokinetics. Among body size measures, total body weight (WT) significantly influenced clearance (CL [L/h]) = 7.42 × (WT/70)<sup>0.75</sup>) and volume of distribution (V [L]) = 12.6 × (WT/70)1). Inter-individual variability decreased after the inclusion of WT, coefficients of variation were reduced from 104% to 58% and from 169% to 83%, for CL and V, respectively. The final model facilitated simulations to achieve target efficacious analgesic and anesthetic concentrations. For analgesia, an initial 10 mcg/kg bolus (for the first hour) followed by an 8 mcg/kg/h infusion (starting at 1 h) achieved the efficacious targeted concentrations (10-100 ng/mL). For procedures that typically require minimal or moderate sedation, a 25 mcg/kg bolus followed by a 20 mcg/kg/h infusion (starting at 5 min) achieved the targeted concentrations (50-200 ng/mL, depending on the procedure). These regimens should be prospectively evaluated to ensure their safety and confirm their efficacy. Overall, this study provides valuable insights into pharmacokinetics and dosing of alfentanil in children.</p>\",\"PeriodicalId\":48908,\"journal\":{\"name\":\"Journal of Clinical Pharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/jcph.70044\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jcph.70044","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

阿芬太尼是一种用于外科手术的阿片类镇痛药和麻醉剂。尽管它在儿童中广泛使用,但美国食品和药物管理局的标签上没有针对12岁以下儿童的具体剂量建议。使用NONMEM (v7.5)进行群体药代动力学分析,以表征阿芬太尼在儿童中的倾向。该研究包括42名接受静脉注射阿芬太尼作为常规护理一部分的患者的58个血浆浓度。中位年龄为7.57岁(范围:0.33-17.80),中位剂量为12.5微克/千克(范围:4-43)。一阶消除的单室模型最好地描述了阿芬太尼的药代动力学。在体型测量中,总体重(WT)显著影响清除率(CL [L/h] = 7.42 × (WT/70)0.75)和分布体积(V [L]) = 12.6 × (WT/70)1)。加入WT后,个体间变异率下降,CL和V的变异系数分别从104%降至58%和169%降至83%。最后的模型有助于模拟,以达到目标有效的镇痛和麻醉浓度。对于镇痛,最初的10微克/千克注射(第一个小时),然后8微克/千克/小时输注(从1小时开始)达到有效的靶向浓度(10-100 ng/mL)。对于通常需要少量或中度镇静的程序,25mcg /kg丸后20mcg /kg/h输注(从5分钟开始)达到目标浓度(50- 200ng /mL,取决于程序)。应对这些方案进行前瞻性评价,以确保其安全性并确认其有效性。总的来说,这项研究为阿芬太尼在儿童中的药代动力学和剂量提供了有价值的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Population Pharmacokinetics of Alfentanil in Children.

Alfentanil is an opioid analgesic and anesthetic agent used in surgical procedures. Despite its widespread use in children, the U.S. Food and Drug Administration label lacks specific dosing recommendations for those under 12 years. A population pharmacokinetic analysis was performed using NONMEM (v7.5) to characterize alfentanil's disposition in children. The study included 58 plasma concentrations from 42 patients who received intravenous alfentanil as part of usual care. Median age was 7.57 years (range: 0.33-17.80) and median dosing was 12.5 mcg/kg (range: 4-43). A one-compartment model with first-order elimination best described alfentanil's pharmacokinetics. Among body size measures, total body weight (WT) significantly influenced clearance (CL [L/h]) = 7.42 × (WT/70)0.75) and volume of distribution (V [L]) = 12.6 × (WT/70)1). Inter-individual variability decreased after the inclusion of WT, coefficients of variation were reduced from 104% to 58% and from 169% to 83%, for CL and V, respectively. The final model facilitated simulations to achieve target efficacious analgesic and anesthetic concentrations. For analgesia, an initial 10 mcg/kg bolus (for the first hour) followed by an 8 mcg/kg/h infusion (starting at 1 h) achieved the efficacious targeted concentrations (10-100 ng/mL). For procedures that typically require minimal or moderate sedation, a 25 mcg/kg bolus followed by a 20 mcg/kg/h infusion (starting at 5 min) achieved the targeted concentrations (50-200 ng/mL, depending on the procedure). These regimens should be prospectively evaluated to ensure their safety and confirm their efficacy. Overall, this study provides valuable insights into pharmacokinetics and dosing of alfentanil in children.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Clinical Pharmacology
Journal of Clinical Pharmacology PHARMACOLOGY & PHARMACY-
自引率
3.40%
发文量
0
期刊介绍: The Journal of Clinical Pharmacology (JCP) is a Human Pharmacology journal designed to provide physicians, pharmacists, research scientists, regulatory scientists, drug developers and academic colleagues a forum to present research in all aspects of Clinical Pharmacology. This includes original research in pharmacokinetics, pharmacogenetics/pharmacogenomics, pharmacometrics, physiologic based pharmacokinetic modeling, drug interactions, therapeutic drug monitoring, regulatory sciences (including unique methods of data analysis), special population studies, drug development, pharmacovigilance, womens’ health, pediatric pharmacology, and pharmacodynamics. Additionally, JCP publishes review articles, commentaries and educational manuscripts. The Journal also serves as an instrument to disseminate Public Policy statements from the American College of Clinical Pharmacology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信